Benefits
Common Cold Duration and Severity Reduction
The Cochrane evidence synthesis covering 31 placebo-controlled clinical trials and 9,745 cold episodes found regular vitamin C supplementation (≥200 mg/day) reduced common cold duration by 8% in adults and 14% in children. A separate evidence synthesis of higher doses (≥1 g/day) found 15% reduction in severity. Vitamin C does not prevent colds in the general population (RR 0.97), but in marathon runners, skiers, and soldiers in cold conditions it halved cold incidence (RR 0.48 across 598 participants).
Iron Absorption Enhancement
Vitamin C dramatically enhances non-heme iron absorption — by 2-6x at typical supplemental doses — by reducing dietary ferric iron (Fe³⁺) to the absorbable ferrous form (Fe²⁺) and forming soluble chelates that resist binding by inhibitors like phytates and polyphenols. This is why vitamin C is co-formulated with iron supplements and recommended alongside plant-source iron in vegetarian and vegan diets. Especially important in iron-deficiency anemia management and pregnancy.
Collagen Synthesis and Wound Healing
Vitamin C is an obligate cofactor for prolyl hydroxylase and lysyl hydroxylase, the enzymes that hydroxylate proline and lysine residues in nascent collagen chains. Without these hydroxylations, collagen cannot form its triple-helical structure or crosslink properly — the molecular basis of scurvy. Adequate vitamin C is essential for wound healing, dental and gum integrity, and connective tissue strength. Deficient patients show impaired surgical recovery, fragile blood vessels, and bleeding gums that resolve within weeks of repletion.
Antioxidant Defense and Glutathione Regeneration
Vitamin C is the primary water-phase antioxidant in plasma, neutralizing reactive oxygen and nitrogen species including superoxide, hydroxyl radical, and peroxynitrite. It also regenerates oxidized vitamin E (α-tocopheroxyl radical) back to active α-tocopherol, providing antioxidant network synergy. Vitamin C maintains intracellular glutathione levels by reducing oxidized glutathione (GSSG) back to GSH, supporting the body's primary intracellular antioxidant system.
Postoperative Atrial Fibrillation Prevention
Pooled analysis of clinical trials in cardiac surgery patients found vitamin C supplementation reduced postoperative atrial fibrillation (POAF) by 32-44% — though effects were strongest in trials outside the US and weaker in larger trials. The mechanism is thought to be reduced oxidative stress during cardiopulmonary bypass. Some guidelines now include vitamin C as a preventive option alongside beta-blockers and amiodarone. Adjunctive role, not first-line monotherapy.
Neurotransmitter and Hormone Synthesis
Vitamin C is a cofactor for dopamine-β-hydroxylase, which converts dopamine to norepinephrine, and for peptidyl glycine α-amidating monooxygenase, which activates peptide hormones. Brain ascorbate concentrations are 10-fold higher than plasma, indicating active transport into neurons. Vitamin C also supports synthesis of carnitine — needed for fatty acid transport into mitochondria — explaining the fatigue and muscle weakness characteristic of deficiency states.
Modest Blood Pressure Reduction
A pooled analysis of 29 clinical trials found 500 mg/day vitamin C reduced systolic blood pressure by approximately 3.84 mmHg and diastolic by 1.48 mmHg in short-term (≤8 weeks) trials. Effect was larger in hypertensive subjects (~4.85/1.67 mmHg). Mechanism likely involves nitric oxide bioavailability and reduced oxidative stress on vascular endothelium. Effect size is small — about half of a thiazide diuretic — but additive to other interventions and side-effect-free at this dose.
Mechanism of action
Free Radical Scavenging and Antioxidant Network
Vitamin C donates electrons to neutralize reactive oxygen and nitrogen species (superoxide, hydroxyl radical, peroxynitrite, peroxyl radicals) in the aqueous compartments of blood and tissues. Once oxidized to dehydroascorbate, it can be regenerated by glutathione or NADH-dependent reductases — making it functionally renewable. It also recycles oxidized vitamin E (α-tocopheroxyl radical) back to its active form, providing antioxidant network synergy that protects lipid membranes.
Collagen Hydroxylation Cofactor
Vitamin C is the essential reducing cofactor for prolyl-4-hydroxylase and lysyl-hydroxylase — the iron-dependent enzymes that hydroxylate proline and lysine residues in pro-collagen chains. Hydroxyproline is required for the triple-helical collagen structure; hydroxylysine is needed for intermolecular crosslinking. Without vitamin C, these enzymes fail and only defective collagen forms — the molecular basis of scurvy symptoms including bleeding gums, joint pain, and impaired wound healing.
Iron Reduction and Absorption Enhancement
Vitamin C reduces dietary ferric iron (Fe³⁺) to ferrous iron (Fe²⁺) in the duodenum — the absorbable form taken up by DMT1 transporters in enterocytes. It also forms soluble ascorbate-iron chelates that resist binding by phytates, polyphenols, and calcium — common inhibitors of non-heme iron uptake. This is why vitamin C is co-administered with iron supplements and why citrus paired with plant-based iron sources is a long-standing nutritional pairing.
Immune Cell Function and Migration
Vitamin C accumulates in neutrophils, lymphocytes, and macrophages at concentrations 50-100x above plasma. It supports neutrophil chemotaxis, phagocytic capacity, and the respiratory burst — the oxidative killing of engulfed pathogens. During infection, neutrophil vitamin C is consumed rapidly, which may explain why supplementation tends to show clearer benefit during physiologic stress (cold exposure, intense exercise) than at baseline.
Epigenetic Regulation via TET and KDM Enzymes
Vitamin C is the reducing cofactor for the ten-eleven translocation (TET) enzymes that demethylate DNA and the Jumonji-domain KDM histone demethylases that erase histone methylation marks. This makes vitamin C an active modulator of epigenetic state — relevant to stem cell biology, embryonic development, and emerging research on hematologic cancers where TET2-loss cancers may be sensitized to high-dose vitamin C as an adjunct.
Neurotransmitter and Carnitine Biosynthesis
Vitamin C is the cofactor for dopamine-β-hydroxylase (which converts dopamine to norepinephrine), peptidyl-glycine α-amidating monooxygenase (which activates peptide hormones), and γ-butyrobetaine hydroxylase (the final step of carnitine biosynthesis). Brain ascorbate concentrations are tightly maintained 10-fold above plasma even in deficiency. Carnitine is needed for fatty acid transport into mitochondria — explaining the early fatigue and muscle weakness of deficient states.
Clinical trials
Cochrane evidence synthesis of placebo-controlled clinical trials testing oral vitamin C (≥200 mg/day) for prevention and treatment of the common cold. Pooled outcomes across incidence, duration, and severity in adults and children.
11,306 participants in 29 incidence trials and 9,745 cold episodes across 31 duration trials.
Regular vitamin C did not prevent colds in the general population (RR 0.97). However, in 598 marathon runners, skiers, and soldiers in cold conditions, incidence was halved (RR 0.48). Cold duration was reduced by 8% in adults and 14% in children. At 1-2 g/day in children, duration was reduced by 18%. Severity also reduced with regular supplementation. Therapeutic dosing started at onset of symptoms showed inconsistent results.
Evidence synthesis of placebo-controlled clinical trials using vitamin C at ≥1 g/day in healthy adults at baseline. Restricted to trials reporting both total cold duration and severity (via scales, severe-stage duration, or days confined indoors).
Pooled across 15 comparisons in 10 randomized double-blind clinical trials.
Vitamin C ≥1 g/day reduced common cold severity by 15% (95% CI 9-21%) vs placebo. Effects were larger on more severe symptoms than mild ones, suggesting symptomatic benefit beyond what duration data alone suggest. Strengthens the dose-response case for ≥1 g/day during cold season versus the lower RDA-level intake.
International, randomized, placebo-controlled clinical trial published in New England Journal of Medicine (2022). 96 hours of IV vitamin C (50 mg/kg every 6 hours) vs placebo in adults admitted to ICU with sepsis from any source.
872 ICU patients with sepsis on vasopressor support.
Primary endpoint negative: no benefit on composite of death or persistent organ dysfunction at 28 days; possible harm signal (35.4% vs 31.6% adverse composite, RR 1.21). Combined with parallel negative trials (CITRIS-ALI, vitamins, ATESS) this definitively ended enthusiasm for high-dose IV vitamin C in sepsis. Practice-changing negative finding.
Randomized, double-blind, placebo-controlled clinical trial published in JAMA (2019). 96 hours of IV vitamin C (50 mg/kg every 6 hours) vs placebo in patients with sepsis and acute respiratory distress syndrome (ARDS).
167 patients with sepsis-associated ARDS.
Primary endpoints negative: no significant differences in modified SOFA score change, C-reactive protein, or thrombomodulin at 96 hours. A secondary 28-day mortality reduction (29.8% vs 46.3%) was widely cited but should be interpreted cautiously after primary endpoint failure. Preceded the larger LOVIT trial that directly contradicted the mortality signal.
Evidence synthesis and pooled analysis of clinical trials of perioperative vitamin C (oral or IV) for prevention of postoperative atrial fibrillation in cardiac surgery and ICU patients. Most included trials used 1-2 g doses.
Pooled across multiple trials in cardiac surgery and ICU populations.
Vitamin C reduced postoperative atrial fibrillation incidence by approximately 32-44%. Heterogeneity was significant — effect strongest in trials conducted outside the US and weaker in larger, more rigorous trials. Considered an adjunctive option in cardiac surgery prophylaxis guidelines alongside beta-blockers and amiodarone, not a first-line monotherapy.
Long-term placebo-controlled cancer prevention clinical trials including SU.VI.Max, Physicians' Health Study II, and Women's Antioxidant Cardiovascular Study. Vitamin C alone or in antioxidant combinations vs placebo for cancer incidence over 5-10+ years.
Tens of thousands of participants across pooled prevention trials.
Primary endpoints negative: vitamin C supplementation did not reduce overall cancer incidence or cancer mortality vs placebo. The Physicians' Health Study II (14,641 male physicians, 8 years, 500 mg/day) was unambiguously negative for prostate, total, and site-specific cancers. Established that oral vitamin C is not effective as a cancer chemoprevention agent.
Pooled analysis of 29 short-term (≤8 weeks) placebo-controlled clinical trials of oral vitamin C supplementation (median 500 mg/day) on systolic and diastolic blood pressure in adults with and without hypertension.
Approximately 1,400 participants across 29 included trials.
Vitamin C 500 mg/day reduced systolic BP by 3.84 mmHg and diastolic by 1.48 mmHg across all participants. Effect was larger in hypertensive subjects (~4.85 mmHg systolic). Effect size modest — roughly half that of a low-dose thiazide — but additive to lifestyle and pharmacologic interventions, with no notable side effects at this dose.
Pooled analysis of 13 placebo-controlled clinical trials of oral vitamin C supplementation on serum uric acid concentrations in healthy adults and those with elevated baseline urate.
556 participants across 13 included trials with serum uric acid endpoints.
Vitamin C supplementation reduced serum uric acid by 0.35 mg/dL on average. However, a subsequent dedicated trial in established gout patients found vitamin C did not reduce serum urate enough for clinical effect and did not prevent gout flares. Surrogate marker improvement (uric acid) did not translate to clinical outcome (gout flares) — a useful cautionary example.